Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions

DiabetesHealthy

Interventions

DRUG

insulin degludec

Single dose administered subcutaneously (s.c., under the skin).

DRUG

placebo

Administered subcutaneously (s.c., under the skin)

DRUG

insulin degludec/insulin aspart 50

Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)

Trial Locations (1)

Neuss